Maxim Group Keeps a Buy Rating on BeiGene (BGNE)

By Ryan Adsit

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on BeiGene (BGNEResearch Report), with a price target of $210.00. The company’s shares closed last Monday at $182.55.

According to, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -19.5% and a 26.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Hancock Jaffe Laboratories, and Lineage Cell Therapeutics.

Currently, the analyst consensus on BeiGene is a Strong Buy with an average price target of $219.71.

See today’s analyst top recommended stocks >>

The company has a one-year high of $210.35 and a one-year low of $108.00. Currently, BeiGene has an average volume of 356.2K.

Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BGNE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290).